| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial.
|
JAMA
|
2009
|
7.78
|
|
2
|
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
|
Ann Intern Med
|
2005
|
6.63
|
|
3
|
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
|
Diabetes Care
|
2005
|
5.77
|
|
4
|
Pioglitazone for diabetes prevention in impaired glucose tolerance.
|
N Engl J Med
|
2011
|
4.28
|
|
5
|
Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program.
|
Diabetes Care
|
2003
|
4.22
|
|
6
|
Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study.
|
Diabetes Care
|
2004
|
4.17
|
|
7
|
Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey.
|
Diabetes Care
|
2006
|
3.72
|
|
8
|
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia.
|
Diabetes Care
|
2014
|
3.31
|
|
9
|
Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial.
|
JAMA
|
2008
|
3.16
|
|
10
|
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors.
|
Diabetes Care
|
2006
|
2.90
|
|
11
|
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
|
Diabetes Care
|
2011
|
2.60
|
|
12
|
Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults.
|
Diabetes Care
|
2007
|
2.20
|
|
13
|
Accuracy of the SEVEN continuous glucose monitoring system: comparison with frequently sampled venous glucose measurements.
|
J Diabetes Sci Technol
|
2009
|
1.93
|
|
14
|
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.
|
J Am Coll Cardiol
|
2008
|
1.91
|
|
15
|
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.
|
Am J Nephrol
|
2003
|
1.85
|
|
16
|
Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.
|
Circulation
|
2010
|
1.75
|
|
17
|
Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.
|
Diabetes Care
|
2009
|
1.58
|
|
18
|
An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes.
|
Diabetes Care
|
2006
|
1.51
|
|
19
|
Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study.
|
Diabetes Care
|
2007
|
1.46
|
|
20
|
Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes.
|
Diabetes Care
|
2011
|
1.26
|
|
21
|
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.
|
Arterioscler Thromb Vasc Biol
|
2012
|
1.22
|
|
22
|
Effectiveness and cost-effectiveness of diabetes prevention among adherent participants.
|
Am J Manag Care
|
2013
|
1.18
|
|
23
|
Impact of computer-generated personalized goals on HbA(1c).
|
Diabetes Care
|
2002
|
1.14
|
|
24
|
Scientific statement: Socioecological determinants of prediabetes and type 2 diabetes.
|
Diabetes Care
|
2013
|
1.09
|
|
25
|
Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group.
|
Diabetes Care
|
2009
|
1.09
|
|
26
|
Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS).
|
Am Heart J
|
2006
|
1.08
|
|
27
|
PREVENTION OF ATHEROSCLEROSIS WITH LDL-C LOWERING - LIPOPROTEIN CHANGES AND INTERACTIONS: THE SANDS STUDY.
|
J Clin Lipidol
|
2009
|
1.02
|
|
28
|
Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk.
|
Diabetes Care
|
2013
|
1.01
|
|
29
|
Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study).
|
Am J Cardiol
|
2004
|
1.01
|
|
30
|
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates.
|
Diabetes
|
2013
|
0.97
|
|
31
|
Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes.
|
Diabetes Care
|
2012
|
0.96
|
|
32
|
Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
|
Clin Ther
|
2008
|
0.93
|
|
33
|
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.
|
J Clin Psychiatry
|
2009
|
0.93
|
|
34
|
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP).
|
Diabetes Metab Res Rev
|
2009
|
0.93
|
|
35
|
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: the "gift" that keeps on giving!
|
Diabetes Care
|
2014
|
0.86
|
|
36
|
The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease.
|
Am J Med
|
2003
|
0.83
|
|
37
|
Novel pharmacologic agents for type 2 diabetes.
|
Endocrinol Metab Clin North Am
|
2005
|
0.83
|
|
38
|
The American Diabetes Association diabetes research perspective.
|
Diabetes
|
2012
|
0.82
|
|
39
|
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).
|
Int J Cardiovasc Imaging
|
2011
|
0.82
|
|
40
|
The American Diabetes Association diabetes research perspective.
|
Diabetes Care
|
2012
|
0.81
|
|
41
|
Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetes.
|
Diabetes Technol Ther
|
2013
|
0.80
|
|
42
|
Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience.
|
J Diabetes Complications
|
2011
|
0.80
|
|
43
|
Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy?
|
Curr Diab Rep
|
2011
|
0.79
|
|
44
|
A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.
|
J Clin Endocrinol Metab
|
2015
|
0.79
|
|
45
|
Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk.
|
Am J Cardiol
|
2006
|
0.78
|
|
46
|
Pramlintide: A new tool in diabetes management.
|
Curr Diab Rep
|
2006
|
0.78
|
|
47
|
Managing people at high risk for diabetes.
|
Ann Intern Med
|
2006
|
0.77
|
|
48
|
Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging.
|
J Nucl Cardiol
|
2006
|
0.77
|
|
49
|
Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: the Stop Atherosclerosis in Native Diabetics Study (SANDS) .
|
J Clin Lipidol
|
2010
|
0.77
|
|
50
|
New concepts in diabetes: how multihormonal regulation can improve glycemic control.
|
J Manag Care Pharm
|
2004
|
0.76
|
|
51
|
Combination pharmacotherapy with incretins: what works best and when?
|
Curr Diab Rep
|
2008
|
0.75
|
|
52
|
Impact of computer-generated personalized goals on cholesterol lowering.
|
Value Health
|
2005
|
0.75
|